Long-Term Survivals of Stage IIB Osteosarcoma: A 20-Year Experience in a Single Institution.
- Author:
Yool CHO
1
;
Gu Hee JUNG
;
So Hak CHUNG
;
Ji Yeon KIM
;
Young CHOI
;
Jae Do KIM
Author Information
- Publication Type:Original Article
- Keywords: Osteosarcoma; Chemotherapy protocol; Long-term survival rate
- MeSH: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*therapeutic use; Bleomycin/administration & dosage; Bone Neoplasms/*drug therapy/*mortality/surgery; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide/administration & dosage; Dactinomycin/administration & dosage; Disease-Free Survival; Doxorubicin/administration & dosage; Female; Follow-Up Studies; Humans; Infant; Kaplan-Meier Estimate; Leucovorin/administration & dosage; Male; Methotrexate/administration & dosage; Middle Aged; Neoadjuvant Therapy; Osteosarcoma/*drug therapy/*mortality/surgery; Survival Rate; Vincristine/administration & dosage; Young Adult
- From:Clinics in Orthopedic Surgery 2011;3(1):48-54
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: The purpose of this study is to evaluate the disease-free survival (DFS) and overall survival (OS) of patients with stage IIB osteosarcoma at a single institution for 20 years and to compare the results according to the chemotherapy protocols. METHODS: From Jan 1988 to Nov 2008, 167 patients with osteosarcoma were treated at our hospital and among them, 117 patients (67 males and 50 females) with stage IIB osteosarcoma were evaluable. Their mean age was 22.6 years (range, 8 months to 71 years). Seventy-eight cases underwent the modified T10 (M-T10) protocol (group 1), 23 cases underwent the T20 protocol (group 2) and 16 cases underwent the T12 protocol (group 3). The DFS and OS were calculated and compared according to the chemotherapy protocols. RESULTS: At a mean follow-up of 78.9 months, 63 patients were continuously disease-free (63/117), 6 patients were alive after having metastatic lesions, 7 patients died of other cause and 41 patients died of their disease. The 5- and 10-year OS rates were 60.2% and 44.8%, respectively and the 5- and 10-year DFS rates were 53.5% and 41.4%, respectively. There was no significant difference of the OS and DFS between the chemotherapy protocols (p = 0.692, p = 0.113). CONCLUSIONS: At present, we achieved success rates close to the internationally accepted DFS and OS. We were able to achieve the higher survival rates using the M-T10 protocol over the 20 years. However, there was no significant difference of results between the chemotherapy protocols. We think the M-T10 protocol will achieve more favorable results in the near future.
